ATLANTA, GA — GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, recognized World Immunization Day on November 10, 2025. The global observance underscores the lifesaving power of vaccines and the urgent need to address rising concerns about vaccine confidence.
“Vaccination remains one of the most powerful tools in modern medicine, preventing millions of deaths each year,” said David A. Dodd, Chairman & CEO of GeoVax. “On World Immunization Day, we reaffirm our commitment to advancing innovative, next-generation vaccines that not only address today’s threats but also restore public trust through transparency, rigorous science, and diversified solutions.”
While over 90% of Americans support routine childhood immunization, surveys show declining confidence in newer vaccines and in the institutions that promote them. This “trust gap” underscores the need for companies like GeoVax to advance safe, transparent, and science-driven vaccine development while communicating openly with patients, providers, and policymakers.
GeoVax’s diversified vaccine platforms, including its COVID-19 vaccine GEO-CM04S1 and its GEO-MVA platform for Mpox and smallpox, are designed to provide broader, more durable immune responses. The company focuses on addressing vulnerable populations, such as the more than 40 million immunocompromised individuals in the U.S., who are often underserved by single-antigen or mRNA-only approaches. Additionally, GeoVax is advancing continuous cell line manufacturing to expand supply, reduce costs, and support U.S. preparedness, aligning with federal initiatives to strengthen domestic biodefense while also providing solutions to global health needs.
“Americans still believe in the power of vaccines,” added Dodd. “The challenge is ensuring that belief carries forward to the next generation of vaccines. By advancing innovation while prioritizing openness and trust, GeoVax is helping to build a future where immunization continues to save lives and protect communities worldwide.”
GeoVax’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as a primary vaccine for immunocompromised patients, a booster vaccine in patients with chronic lymphocytic leukemia, and a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the company is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation. For more information, visit www.geovax.com.
